Although the COVID‐19 pandemic has officially ended, the persistent challenge of long‐
COVID or post‐acute COVID sequelae (PASC) continues to impact societies globally …

The development of mouse models for coronavirus disease 2019 (COVID-19) has enabled
testing of vaccines and therapeutics and defining aspects of severe acute respiratory …

ABSTRACT A comprehensive analysis and characterization of a severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection model that mimics non-severe and severe …

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
continues to progress quickly, with over 36 million people infected and over 1 million deaths …

ABSTRACT Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged in
late 2019 and has spread worldwide resulting in the Coronavirus Disease 2019 (COVID-19) …

Abstract The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) remains a
public health concern and a subject of active research effort. Development of pre-clinical …

Despite tremendous progress in the understanding of COVID-19, mechanistic insight into
immunological, disease-driving factors remains limited. We generated maVie16, a mouse …

Since December 2019, a novel coronavirus SARS-CoV-2 has emerged and rapidly spread
throughout the world, resulting in a global public health emergency. The lack of vaccine and …

Since its discovery in December 2019, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused over 146 million cases of Coronavirus Disease 2019 (COVID …

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) uses full-length
angiotensin converting enzyme 2 (ACE2), which is membrane bound, as its initial cell …